Back to search
FDAFDA · Food and drugs·Recall number D-0509-2024

Cathflo activase (ALTEPLASE), 2mg vials, Rx only, Genentech Inc., South San Francisco, CA 94080, NDC 50242-041-64

Published June 5, 2024 · Recall initiated: May 20, 2024

Summary

FDA records drug Class II recall D-0509-2024, published June 5, 2024 and initiated May 20, 2024. Recalling firm: Genentech, Inc.; Status: Terminated; Reported quantity: Lot:3618858 = 105,759; Lot:3618873 =90,359; Lot: Lot #: 3618858, 3618873, Exp. Date 01/31/2026. Class II means possible temporary or medically reversible effects, or a remote probability of serious health consequences.

Status when published: Terminated — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.

What's the hazard

Lack of Assurance of Sterility: Deformed stoppers observed during filling operations for Cathflo Activase.

What to do

Voluntary: Firm initiated · Letter

Get an email if CATHFLO ACTIVASE has another recall

Free. We only write when there's a new recall that matches. Unsubscribe in one click.

Recall details

Brand
CATHFLO ACTIVASE
Manufacturer
Genentech, Inc.
Distributor
Nationwide within the United States
Lot
Lot #: 3618858, 3618873, Exp. Date 01/31/2026
Risk classification
Class II
Area (FDA)
drug
Country
United States

Related recalls

Questions about this recall

Was Cathflo activase (ALTEPLASE), 2mg vials, Rx only, Genentech Inc., South San Francisco, CA 94080, NDC 50242-041-64 recalled?

Yes. FDA published recall D-0509-2024 on June 5, 2024. Reported hazard: Lack of Assurance of Sterility: Deformed stoppers observed during filling operations for Cathflo Activase.

What should I do if I have this product?

Voluntary: Firm initiated · Letter

How do I know if my unit is part of the recall?

Compare your product details with the notice. Brand: CATHFLO ACTIVASE.